ClinicalTrials.gg
Not yet recruitingNCT07778641Updated Aug 21, 2026

Genetic Study of OTOF- Related Auditory Neuropathy Spectrum Disorder

An observational study in Auditory Neuropathy Spectrum Disorder and Auditory Neuropathy, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Sohag University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
30
Sex
All
01

Study summary

The aim of this observational study is to determine the prevalence of OTOF gene variants among patients with auditory neuropathy spectrum disorder (ANSD). The primary research question is whether patients with ANSD carry a pathogenic or likely pathogenic OTOF gene variant. Participants will undergo genetic analysis of the OTOF gene.

02

Conditions studied

  • Auditory Neuropathy Spectrum Disorder
  • Auditory Neuropathy

Keywords

  • Otoferlin
  • Auditory neuropathy spectrum disorder
  • ANSD
  • Auditory synaptopathy
  • Genetic Testing
  • Whole Exome Sequencing
  • OTOF mutation
  • Hereditary hearing loss
  • Molecular testing
  • OTOF
  • OTOF Variants
03

In context

Lead sponsor

Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of patients diagnosed with auditory neuropathy spectrum disorder (ANSD) who meet the predefined eligibility criteria and attend the participating audiology/otolaryngology clinic during the study recruitment period. Eligible participants will undergo genetic analysis to assess for pathogenic or potentially pathogenic variants in the OTOF gene. Participants may include children and adults with ANSD, regardless of sex.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The study will be including 30 subjects of 30 patients of both sexes of any age with congenital hearing loss and confirmed diagnosis of non-syndromic ANSD:

    A) Disproportionate speech discrimination score (SDS) with the hearing threshold level.

    B)The auditory brainstem response (ABR) test with no waveform, disturbed waves, nor detectable wave V at high intense stimulus.

    C) The otoacoustic emission (OAE) and/or cochlear microphonic (CM) potential may be present.

  2. .

Exclusion criteria

Exclusion Criteria:

  • 1) Known acquired risk factors of ANSD as preterm, hypoxia, hyperbilirubinemia. 2) Conductive hearing loss. 3) Syndromic ANSD hearing loss. 3) Binaural cochlear implants. 4) Inner ear malformation, cochlear nerve aplasia or hypoplasia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Patients with auditory neuropathy spectrum disorder

    Diagnostic Test: Whole exome sequencing.

Interventions

  • Diagnostic testWhole exome sequencing.

    Whole exome sequencing (WES) will be performed on a biological sample obtained from each eligible participant to analyze the protein-coding regions of the genome. The analysis will specifically assess the OTOF gene for genetic variants associated with auditory neuropathy spectrum disorder (ANSD), while other clinically relevant variants identified through the sequencing may also be documented according to the study protocol. Identified OTOF variants will be classified according to established variant-interpretation criteria.

06

What researchers measure

Primary outcomes

  1. Study OTOF gene variants among patients with non-syndromic auditory neuropathy spectrum disorder

    Time frame: At baseline, following enrollment and confirmation of eligibility.

07

Study locations

1 site
08

References and documents

Publications

  • Zhang QJ, Han B, Lan L, Zong L, Shi W, Wang HY, Xie LY, Wang H, Zhao C, Zhang C, Yin ZF, Wang DY, Petit C, Guan J, Wang QJ. High frequency of OTOF mutations in Chinese infants with congenital auditory neuropathy spectrum disorder. Clin Genet. 2016 Sep;90(3):238-46. doi: 10.1111/cge.12744. Epub 2016 Mar 11. PubMed 26818607 ↗
  • Yong N, Cao M, Anderson E, Downie L, Rance G, Bai J, Liddle K, Howard A, Smith L, Sung V, Wang J. The Genetic Causes of Auditory Neuropathy: A Systematic Review. J Clin Med. 2026 May 31;15(11):4260. doi: 10.3390/jcm15114260. PubMed 42279121 ↗
  • Vignesh SS, Jaya V, Muraleedharan A. Prevalence and Audiological Characteristics of Auditory Neuropathy Spectrum Disorder in Pediatric Population: A Retrospective Study. Indian J Otolaryngol Head Neck Surg. 2016 Jun;68(2):196-201. doi: 10.1007/s12070-014-0759-6. Epub 2014 Aug 12. PubMed 27340636 ↗
  • Valayannopoulos V, Bance M, Carvalho DS, Greinwald JH Jr, Harvey SA, Ishiyama A, Landry EC, Lowenheim H, Lustig LR, Manrique M, Nash R, Polo R, Pritchett CV, Rubinstein JT, Shearer AE, Del Castillo I, Anderson JJ, Corrales CE, Quigley TM, Riggs WJ, Weber P, Wilson G, Irvin SC, Hassan HE, Chen Y, Liu R, Drummond MC, Sabin LR, Musser BJ, Yancopoulos GD, Kyratsous CA, Herman GA, Baras A, Whitton JP; CHORD Study Group. DB-OTO Gene Therapy for Inherited Deafness. N Engl J Med. 2026 Mar 12;394(11):1074-1083. doi: 10.1056/NEJMoa2400521. Epub 2025 Oct 12. PubMed 41085057 ↗
  • Thorpe RK, Azaiez H, Wu P, Wang Q, Xu L, Dai P, Yang T, Schaefer GB, Peters BR, Chan KH, Schatz KS, Bodurtha J, Robin NH, Hirsch Y, Rahbeeni ZA, Yuan H, Smith RJH. The natural history of OTOF-related auditory neuropathy spectrum disorders: a multicenter study. Hum Genet. 2022 Apr;141(3-4):853-863. doi: 10.1007/s00439-021-02340-w. Epub 2021 Aug 23. PubMed 34424407 ↗
  • Strenzke N, Chakrabarti R, Al-Moyed H, Muller A, Hoch G, Pangrsic T, Yamanbaeva G, Lenz C, Pan KT, Auge E, Geiss-Friedlander R, Urlaub H, Brose N, Wichmann C, Reisinger E. Hair cell synaptic dysfunction, auditory fatigue and thermal sensitivity in otoferlin Ile515Thr mutants. EMBO J. 2016 Dec 1;35(23):2519-2535. doi: 10.15252/embj.201694564. Epub 2016 Oct 11. PubMed 27729456 ↗
  • Shearer AE, Hansen MR. Auditory synaptopathy, auditory neuropathy, and cochlear implantation. Laryngoscope Investig Otolaryngol. 2019 Jul 1;4(4):429-440. doi: 10.1002/lio2.288. eCollection 2019 Aug. PubMed 31453354 ↗
  • Sanyelbhaa Talaat H, Kabel AH, Samy H, Elbadry M. Prevalence of auditory neuropathy (AN) among infants and young children with severe to profound hearing loss. Int J Pediatr Otorhinolaryngol. 2009 Jul;73(7):937-9. doi: 10.1016/j.ijporl.2009.03.009. Epub 2009 May 5. PubMed 19409623 ↗
  • Santarelli R, Scimemi P, Costantini M, Dominguez-Ruiz M, Rodriguez-Ballesteros M, Del Castillo I. Cochlear Synaptopathy due to Mutations in OTOF Gene May Result in Stable Mild Hearing Loss and Severe Impairment of Speech Perception. Ear Hear. 2021 Nov-Dec 01;42(6):1627-1639. doi: 10.1097/AUD.0000000000001052. PubMed 33908410 ↗
  • Saidia AR, Ruel J, Bahloul A, Chaix B, Venail F, Wang J. Current Advances in Gene Therapies of Genetic Auditory Neuropathy Spectrum Disorder. J Clin Med. 2023 Jan 17;12(3):738. doi: 10.3390/jcm12030738. PubMed 36769387 ↗
  • Michalski N, Goutman JD, Auclair SM, Boutet de Monvel J, Tertrais M, Emptoz A, Parrin A, Nouaille S, Guillon M, Sachse M, Ciric D, Bahloul A, Hardelin JP, Sutton RB, Avan P, Krishnakumar SS, Rothman JE, Dulon D, Safieddine S, Petit C. Otoferlin acts as a Ca2+ sensor for vesicle fusion and vesicle pool replenishment at auditory hair cell ribbon synapses. Elife. 2017 Nov 7;6:e31013. doi: 10.7554/eLife.31013. PubMed 29111973 ↗
  • Kitao K, Mutai H, Namba K, Morimoto N, Nakano A, Arimoto Y, Sugiuchi T, Masuda S, Okamoto Y, Morita N, Sakamoto H, Shintani T, Fukuda S, Kaga K, Matsunaga T. Deterioration in Distortion Product Otoacoustic Emissions in Auditory Neuropathy Patients With Distinct Clinical and Genetic Backgrounds. Ear Hear. 2019 Jan/Feb;40(1):184-191. doi: 10.1097/AUD.0000000000000586. PubMed 29688962 ↗
  • Kim BJ, Jang JH, Han JH, Park HR, Oh DY, Lee S, Kim MY, Kim AR, Lee C, Kim NKD, Park WY, Choung YH, Choi BY. Mutational and phenotypic spectrum of OTOF-related auditory neuropathy in Koreans: eliciting reciprocal interaction between bench and clinics. J Transl Med. 2018 Nov 27;16(1):330. doi: 10.1186/s12967-018-1708-z. PubMed 30482216 ↗
  • Hams N, Padmanarayana M, Qiu W, Johnson CP. Otoferlin is a multivalent calcium-sensitive scaffold linking SNAREs and calcium channels. Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8023-8028. doi: 10.1073/pnas.1703240114. Epub 2017 Jul 10. PubMed 28696301 ↗
  • Berlin CI, Morlet T, Hood LJ. Auditory neuropathy/dyssynchrony: its diagnosis and management. Pediatr Clin North Am. 2003 Apr;50(2):331-40, vii-viii. doi: 10.1016/s0031-3955(03)00031-2. PubMed 12809326 ↗
  • Bielecki I, Horbulewicz A, Wolan T. Prevalence and risk factors for auditory neuropathy spectrum disorder in a screened newborn population at risk for hearing loss. Int J Pediatr Otorhinolaryngol. 2012 Nov;76(11):1668-70. doi: 10.1016/j.ijporl.2012.08.001. Epub 2012 Aug 29. PubMed 22939890 ↗
  • Ford CL, Riggs WJ, Quigley T, Keifer OP Jr, Whitton JP, Valayannopoulos V. The natural history, clinical outcomes, and genotype-phenotype relationship of otoferlin-related hearing loss: a systematic, quantitative literature review. Hum Genet. 2023 Oct;142(10):1429-1449. doi: 10.1007/s00439-023-02595-5. Epub 2023 Sep 7. PubMed 37679651 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Jan 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2026
First posted
Aug 21, 2026
StartEst.
Aug 2026
Primary completionEst.
Jan 2027
CompletionEst.
Feb 2027
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07778641
Lead sponsor
Sohag University
Responsible party
Mira Ayman Ramzy (Audio-vestibular medicine resident doctor, Sohag University) — Principal investigator
First posted
Aug 21, 2026
Start date
Aug 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Aug 21, 2026

Study contacts

Mira Ayman Ramzy
Contact
mira_ayman99@yahoo.com
+201273979650
Mostafa Ahmed Aly Youssif, Professor
Contact
+201001313395

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion